Evidence map›Paper›PMID 42828104›Full record

ArticleMaterials today. Bio2026

A USP8-targeting nanoamplifier synergizes with radiotherapy to remodel the immunosuppressive tumor microenvironment in lung cancer.

Junjian Deng, Peiyi Luo, Kejun Li, Miaomiao Zhang, Ruxin Zhang, Zengxing Zhang, Songlin Wang, Yongfa Zheng

Abstract read
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junjian DengDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
Peiyi LuoDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
Kejun LiDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
Miaomiao ZhangDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
Ruxin ZhangDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.
Zengxing ZhangDepartment of Oncology, Wuxue First People's Hospital, Wuxue, Hubei, 435401, China.
Songlin WangDepartment of Oncology, Zhongxiang City People's Hospital, Zhongxiang, Hubei, 431900, China.
Yongfa ZhengDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.

Funding

Wellcome Trust FC001206
6 · The paper itself

Abstract

Radiotherapy (RT) remains a cornerstone in lung cancer treatment, but its efficacy is often limited by radioresistance and an immunosuppressive tumor microenvironment (TME). Here, we identify the deubiquitinating enzyme USP8 as a key regulator of M2-like tumor-associated macrophages (TAMs) in the irradiated TME. To exploit this finding, we developed a biomimetic nanoparticle, USP8@CPMOF, which co-delivers a USP8 inhibitor and an anti-PD-L1 nanobody-coated membrane. This nanosystem specifically targets both irradiated tumor cells and TAMs, responding to the acidic and high-glutathione TME to trigger ferroptosis and release the USP8 inhibitor.

Indexed as

FerroptosisNanoparticleRadiotherapyTumor microenvironmentUSP8

Identifiers

PMID42828104
PMCPMC13631627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.